Vertex Pharmaceuticals Incorporated (VRTX) on Decifer

Decifer ranks VRTX number 113 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 18% and it turns most of its profit into real cash.
• Revenue is expected to grow about 10% a year, profits grew 843% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong 18% returns, profits up 843%, and momentum of 13 out of 35 are solid, but with no stated reason to grow in our worldview it stops short of the top tier.

The current read

The evidence on VRTX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Vertex Pharmaceuticals Incorporated operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full VRTX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.